174 related articles for article (PubMed ID: 11804277)
1. Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas.
Konstantinidou A; Korkolopoulou P; Patsouris E; Mahera H; Hranioti S; Kotsiakis X; Davaris P
J Neurooncol; 2001 Oct; 55(1):1-9. PubMed ID: 11804277
[TBL] [Abstract][Full Text] [Related]
2. Detection of apoptotic cells in archival tissue from diffuse astrocytomas using a monoclonal antibody to single-stranded DNA.
Korkolopoulou PA; Konstantinidou AE; Patsouris ES; Christodoulou PN; Thomas-Tsagli EA; Davaris PS
J Pathol; 2001 Mar; 193(3):377-82. PubMed ID: 11241419
[TBL] [Abstract][Full Text] [Related]
3. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas.
Konstantinidou AE; Korkolopoulou P; Kavantzas N; Mahera H; Thymara I; Kotsiakis X; Perdiki M; Patsouris E; Davaris P
Histol Histopathol; 2003 Jan; 18(1):67-74. PubMed ID: 12507285
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
Karamitopoulou E; Perentes E; Tolnay M; Probst A
Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
[TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.
Konstantinidou AE; Patsouris E; Korkolopoulou P; Kavantzas N; Mahera H; Davaris P
Histopathology; 2001 Oct; 39(4):402-8. PubMed ID: 11683942
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA: relation to cell cycle regulators and survival.
Korkolopoulou P; Konstantinidou AE; Christodoulou P; Patsouris E; Thomas-Tsangli E; Kapralos P; Davaris P
Urology; 2000 Sep; 56(3):516-20. PubMed ID: 10962336
[TBL] [Abstract][Full Text] [Related]
7. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
8. Elevated p53 expression in benign meningiomas protects against recurrence and may be indicative of senescence.
Hakin-Smith V; Battersby RD; Maltby EL; Timperley WR; Royds JA
Neuropathol Appl Neurobiol; 2001 Feb; 27(1):40-9. PubMed ID: 11299001
[TBL] [Abstract][Full Text] [Related]
9. Expression of apoptotic and proliferation markers in meningiomas.
Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
[TBL] [Abstract][Full Text] [Related]
10. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
[TBL] [Abstract][Full Text] [Related]
11. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
Abramovich CM; Prayson RA
Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
[TBL] [Abstract][Full Text] [Related]
13. Caspase-3 immunohistochemical expression is a marker of apoptosis, increased grade and early recurrence in intracranial meningiomas.
Konstantinidou AE; Givalos N; Gakiopoulou H; Korkolopoulou P; Kotsiakis X; Boviatsis E; Agrogiannis G; Mahera H; Patsouris E
Apoptosis; 2007 Apr; 12(4):695-705. PubMed ID: 17143787
[TBL] [Abstract][Full Text] [Related]
14. Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence.
Csonka T; Murnyák B; Szepesi R; Bencze J; Bognár L; Klekner A; Hortobágyi T
Folia Neuropathol; 2016; 54(2):114-26. PubMed ID: 27543769
[TBL] [Abstract][Full Text] [Related]
15. Growth rate of intracranial meningioma: tumor doubling time and proliferating cell nuclear antigen staining index.
Ide M; Jimbo M; Yamamoto M; Umebara Y; Hagiwara S; Kubo O
Neurol Med Chir (Tokyo); 1995 May; 35(5):289-93. PubMed ID: 7623949
[TBL] [Abstract][Full Text] [Related]
16. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
Yang SY; Park CK; Park SH; Kim DG; Chung YS; Jung HW
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):574-80. PubMed ID: 17766430
[TBL] [Abstract][Full Text] [Related]
17. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas.
Kim CH; Cheong JH; Bak KH; Kim JM; Oh SJ
J Clin Neurosci; 2001 May; 8 Suppl 1():44-8. PubMed ID: 11386825
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis in breast carcinoma.
González-Cámpora R; Galera Ruiz MR; Vázquez Ramírez F; Ríos Martín JJ; Fernández Santos JM; Ramos Martos MM; Gómez Pascual A
Pathol Res Pract; 2000; 196(3):167-74. PubMed ID: 10729921
[TBL] [Abstract][Full Text] [Related]
19. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.
Maiuri F; De Caro MB; Esposito F; Cappabianca P; Strazzullo V; Pettinato G; de Divitiis E
J Neurooncol; 2007 Mar; 82(1):63-8. PubMed ID: 17225937
[TBL] [Abstract][Full Text] [Related]
20. AKT2 expression in histopathologic grading and recurrence of meningiomas.
Wang Q; Fan SY; Qian J; Wang JY; Lu YC; Hu GH; Luo C
Eur J Surg Oncol; 2014 Sep; 40(9):1056-61. PubMed ID: 24656454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
